Host |
Mouse |
Klon |
1306/156 |
Format |
Purified |
Methode |
EL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Native |
Trichomonas vaginalis (Strain 1)
|
Zytomed Systems GmbH |
1306/156 |
200 µg |
Purified |
RUO |
620-0265 |
-
|
Host |
Rabbit |
Klon |
EPR17341 |
Format |
Concentrate |
Methode |
P, IF, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Astrocytoma, cerebral cortex tissue |
Verdünnung |
1:500 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide within Human Pan Trk aa 800 to the C-terminus. The exact sequence is proprietary. |
Lokalisation |
Cytoplasm |
TrkA + TrkB + TrkC
|
Abcam |
EPR17341 |
0.1 ml |
Concentrate |
RUO |
AB181560 |
-
|
Host |
Rabbit |
Klon |
SP293 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
0.5 ml |
Concentrate |
RUO |
520-5932 |
-
|
Host |
Rabbit |
Klon |
SP293 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the C-terminus of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP293 |
1 ml |
Concentrate |
RUO |
520-5934 |
-
|
Host |
Rabbit |
Klon |
SP294 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
0.5 ml |
Concentrate |
RUO |
520-5942 |
-
|
Host |
Rabbit |
Klon |
SP294 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP294 |
1 ml |
Concentrate |
RUO |
520-5944 |
-
|
Host |
Rabbit |
Klon |
SP295 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
0.5 ml |
Concentrate |
RUO |
520-5952 |
-
|
Host |
Rabbit |
Klon |
SP295 |
Format |
Concentrate |
Reaktivität |
MS |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human TROP-2 protein |
Lokalisation |
Cell membrane |
TROP-2
|
Zytomed Systems GmbH |
SP295 |
1 ml |
Concentrate |
RUO |
520-5954 |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
1 ml |
Concentrate |
CE/IVD |
Z2744RL |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
7 ml |
ready-to-use |
CE/IVD |
Z2744RP |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.5 ml |
Concentrate |
CE/IVD |
Z2744RS |
-
|
Host |
Rabbit |
Klon |
ZR388 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Breast or colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human TACSTD2 protein (around aa 31-274) (exact sequence is proprietary) |
Lokalisation |
Cell Surface |
TROP2
|
Zeta Corporation |
ZR388 |
0.1 ml |
Concentrate |
CE/IVD |
Z2744RT |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
1 ml |
Concentrate |
CE/IVD |
Z2673RL |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
r-t-u |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
gebrauchsfertig |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
7 ml |
r-t-u |
CE/IVD |
Z2673RP |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.5 ml |
Concentrate |
CE/IVD |
Z2673RS |
-
|
Host |
Rabbit |
Klon |
ZR382 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal breast, breast carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized peptide corresponding to the C-terminus of human TRPS1 protein |
Lokalisation |
Nuclear |
TRPS1
|
Zeta Corporation |
ZR382 |
0.1 ml |
Concentrate |
CE/IVD |
Z2673RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P, WB, EL |
Vorbehandlung |
Fast Enzyme, Pepsin |
Positivkontrolle |
Pancreas |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified trypsin from human pancreas |
Lokalisation |
Cytoplasmic, extracellular |
Trypsin (Human pancreatic)
|
Zytomed Systems GmbH |
polyclonal |
0.2 ml |
Concentrate |
RUO |
RBK055-02 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.1 ml |
Concentrate |
RUO |
520-17500 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
520-17502 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Anterior Pituitary |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Purified human TSH |
Lokalisation |
Cytoplasm |
TSH (Thyroid Stimulating Hormone)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-17504 |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2069ML |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2069MP |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2069MS |
-
|
Host |
Mouse |
Klon |
8G7G3/1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Normal thyroid or lung. |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Rat TTF-1 recombinant protein |
Lokalisation |
Nucleus |
TTF-1
|
Zeta Corporation |
8G7G3/1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2069MT |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3126A |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
1 ml |
Concentrate |
CE/IVD |
ACI3126C |
-
|
Host |
Mouse |
Klon |
SPT24 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung Adeno-CA |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Nuclear |
TTF-1 (Thyroid Transcription Factor 1)
|
Biocare Medical |
SPT24 |
6 ml |
Ready-to-use |
CE/IVD |
API3126AA |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
1 ml |
Concentrate |
CE/IVD |
Z2370RL |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
7 ml |
Ready-to-use |
CE/IVD |
Z2370RP |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
0.5 ml |
Concentrate |
CE/IVD |
Z2370RS |
-
|
Host |
Rabbit |
Klon |
ZR176 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal thyroid or lung |
Verdünnung |
1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant TTF-1 protein |
Lokalisation |
Nucleus |
TTF-1 (Thyroid Transcription Factor 1)
|
Zeta Corporation |
ZR176 |
0.1 ml |
Concentrate |
CE/IVD |
Z2370RT |
-
|
Host |
Mouse + Rabbit |
Klon |
8G7G3/1+EP42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung adenocarcinoma and lung squamouse cell carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG1 |
Lokalisation |
Nucleus and cytoplasm |
TTF-1 + Cytokeratin 5
|
Biocare Medical |
8G7G3/1+EP42 |
6 ml |
Ready-to-use |
CE/IVD |
PM425DSAA |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
1:50 |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
1 ml |
Concentrate |
RUO |
CO004K |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
1:50 |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
0.5 ml |
Concentrate |
RUO |
CO004K-05 |
-
|
Host |
Mouse |
Klon |
8G7G3/1+D5/16B4 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung, Skin |
Verdünnung |
- |
Isotyp |
Mouse |
Lokalisation |
Nuclear, Cytoplasmic |
TTF-1 + Cytokeratin 5/6 Cocktail
|
Zytomed Systems GmbH |
8G7G3/1+D5/16B4 |
6 ml |
Ready-to-use |
RUO |
COG004 |
-
|
Host |
Mouse + Rabbit |
Klon |
8G7G3/1+BC15 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1+Rabbit IgG |
Lokalisation |
Nucleus and cytoplasm (granular) |
TTF-1 + Napsin A
|
Biocare Medical |
8G7G3/1+BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3078DSAA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide from aa 426-450 of human tubulin alpha. |
Lokalisation |
Cytoplasm |
Tubulin, alpha
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-4134 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from aa 416-430 of human tubulin beta. |
Lokalisation |
Cytoplasm |
Tubulin, beta
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
520-3812 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB, IP |
Vorbehandlung |
- |
Positivkontrolle |
Skin, Lung |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from aa 416-430 of human tubulin beta. |
Lokalisation |
Cytoplasm |
Tubulin, beta
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
520-3814 |
-
|
Host |
Mouse |
Klon |
TU-20 |
Format |
Purified |
Methode |
F, P, WB |
Vorbehandlung |
Citrate pH6 ! (KD 30.6.09) |
Positivkontrolle |
Neuronal Tisuue |
Verdünnung |
1:50 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Synthetic peptide corresponding to an epitope within the C-terminal region of human class III beta tubulin |
Tubulin, beta 3
|
Zytomed Systems GmbH |
TU-20 |
100 µg |
Purified |
RUO |
620-0318 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
1 ml |
Concentrate |
CE/IVD |
MOB290 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
0.1 ml |
Concentrate |
CE/IVD |
MOB290-01 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
0.5 ml |
Concentrate |
CE/IVD |
MOB290-05 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Diagnostic Biosystems |
T311 |
6 ml |
Ready-to-use |
CE/IVD |
PDM150 |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
1.0 ml |
Concentrate |
CE/IVD |
Z2074ML |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
7 ml |
Ready-to-use |
CE/IVD |
Z2074MP |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
0.5 ml |
Concentrate |
CE/IVD |
Z2074MS |
-
|
Host |
Mouse |
Klon |
T311 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant tyrosinase protein |
Lokalisation |
Cytoplasm |
Tyrosinase
|
Zeta Corporation |
T311 |
0.1 ml |
Concentrate |
CE/IVD |
Z2074MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
F, P, WB, IF |
Verdünnung |
1:1000 |
Isotyp |
Rabbit IgG |
Verdünnung |
Tyrosine Hydroxylase purified from Pheochromocytoma |
Tyrosine Hydroxylase
|
Zytomed Systems GmbH |
polyclonal |
100 µl |
Purified |
RUO |
620-0336 |
-
|
Host |
Mouse |
Klon |
1B4-UB |
Format |
Purified |
Methode |
F, EL, WB, FL, P |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Ubiquitin from bovine erythrocytes conjugated to bovine gamma globulin |
Ubiquitin
|
Zytomed Systems GmbH |
1B4-UB |
100 µg |
Purified |
RUO |
621-0004 |
-
|